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Short title: 
Continue or change pre-existing AP? 
ABSTRACT 
Introduction: Antiplatelet therapy is routinely prescribed early after ischaemic stroke. 
Many patients will already be taking antiplatelet therapy and it is unknown whether 
these patients should continue the same antiplatelet treatment or switch to a different 
regimen.  
Methods: We selected patients with ischaemic stroke from the Virtual International 
Stroke Trials Archive (VISTA) database who were prescribed anti-platelets both 
before and after their stroke and who had detailed records of adverse events after stroke. 
We compared patients who changed to a new antiplatelet regimen after their stroke to 
those who continued the same regimen. The primary outcome was recurrent ischaemic 
stroke within 90 days after their index stroke and for secondary outcome was 
intracerebral haemorrhage (ICH) or extracranial haemorrhage (ECH). We used logistic 
regression analysis and adjusted for age and baseline NIHSS.  
Results: A total of 1129 participants were included. Of these, 538 subjects changed 
antiplatelet regimen post stroke and 591 continued the same regimen. A recurrent 
ischaemic event occurred in 4.1% of subjects who changed regimen and 4.3% who 
continued unchanged (adjusted OR=0.93; 95% CI 0.54-1.75, p=0.929). The incidence 
of ICH and ECH within the first 90 days was similar in both groups (2.4% vs. 2.6% 
(adjusted OR=1.02; 95% CI 0.48-2.18, p=0.955) and 4.7% vs. 2.9% (adjusted OR=1.82; 
95% CI 0.96-3.43, p=0.065) respectively). 
Conclusion: In patients who suffer ischaemic stroke whilst taking antiplatelets, a 
change in antiplatelet regimen was not associated with an altered risk of early recurrent 
ischaemic stroke rate or bleeding. However, the results must be interpreted in view of 
the low event rates. 
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Introduction 
Antiplatelet therapy is recommended for patients with ischaemic stroke or transient 
ischaemic attack (TIA) due to atherosclerotic disease.1 Antiplatelet drugs are prescribed 
to prevent further ischaemic stroke, minimize the risk of early death and to improve 
long-term outcome.2, 3  
 
Guidelines recommend that antiplatelet regimens choices are individualised based on 
numerous factors including patient risk factor profiles, cost, tolerability and relative 
effectiveness.4 One potentially important factor is pre-existing anti-platelet therapy. In 
the recently published CHANCE study, at least 20% of patients had history of previous 
stroke and 11% of patients had their index stroke whilst taking antiplatelet therapy.5 
Guidelines acknowledge that in patients who experience a stroke whilst taking 
antiplatelet therapy, there are no clinical trials to show whether switching antiplatelet 
agents decreases the risk of subsequent events.6 There are reasons why switching 
regimen may be advantageous. Failure of antiplatelet treatment could be due to disease 
severity (no drug will be 100% effective), lack of adherence or resistance to effect of the 
antiplatelet drug. Resistance to clopidogrel and aspirin exists and studies have shown 
that aspirin resistance is associated with an increased risk of cardiovascular events.7 It is 
possible resistant patients should be switched to another class of antiplatelet. 
 
In the absence of clinical trial data, we sought to assess whether switching 
antiplatelet regimens associated with better outcome than continuing the same 
therapy in patients already taking anti-platelet therapy at the time of acute 
ischaemic stroke. We hypothesized that a change of antiplatelet regimen would 
reduce cardiovascular event rate without increasing bleeding.  
 Methods 
We used data contained in the Virtual International Stroke Trials Archive (VISTA) 
database where have been described previously.8 VISTA data are stored at the 
Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK. It 
provides access to anonymised data collated from completed and monitored 
clinical trials. Within VISTA, demographic data such as age, sex and ethnicity; 
smoking history and comorbidities as well as details on the index stroke, and 
functional outcome measures are contained. Information on adverse events (AE), 
serious adverse events (SAE), laboratory measurements and prescribed 
medications are also available from certain trials. All clinical trials within VISTA 
already have local institutional review board approved procedures in accordance 
with the Declaration of Helsinki. Access to data was approved by the VISTA 
steering committee. 
 
We included patients who had suffered ischaemic stroke whilst taking antiplatelet 
drugs (for at least 7 days prior) and who were recommenced on antiplatelet 
therapy within 90 days after ischaemic stroke where data on baseline 
characteristics, medical history, baseline National Institutes of Health Stroke Scale 
(NIHSS), occurrence of adverse and serious adverse events, and medication use 
with start dates were recorded in VISTA. We extracted data for these patients. 
 
Data on antiplatelet treatments were based on platelet aggregation inhibitors (which 
includes derivatives of salicylic acid, thienopyridine and dipyridamole). Participants 
were grouped according to whether they changed antiplatelet regimen (change group) or 
continued on the same antiplatelet therapy (continue group). 
 
Our primary outcome was the occurrence of recurrent ischaemic stroke and the 
secondary outcome was bleeding complications within 90 days post-stroke. The 
modified Rankin Scale (mRS) at 90 days was used to measure the functional 
outcomes. We extracted information about recurrent ischaemic stroke and 
bleeding complications in all patients from AE and SAE reports. We defined a 
recurrent ischaemic stroke as a clear statement of a new adverse event including 
terms ischaemic stroke, cerebral infarction or cerebrovascular accident. We did 
not include events such as worsening of initial stroke symptoms or oedema. For 
bleeding complication, the event was identifies using these key terms: hematoma, 
haemorrhage, bleeding, blood or melaena. Bleeding complications were 
categorized into two i.e. intracerebral haemorrhage (ICH) and extracranial 
haemorrhage (ECH). Intracerebral haemorrhage was defined as any ICH but 
excluding haemorrhagic transformation infarction 1 and 2, whereas, ECH was 
defined as any bleeding episode from another source. 
 
Statistical analysis 
We compared baseline variables in the change and continue groups. Categorical 
variables were summarised using frequencies and proportions and were compared using 
the Chi-square test or Fisher’s exact test, where appropriate. Continuous variables were 
summarised using mean [standard deviation (SD)] or median [interquartile range (IQR)] 
and were compared using Student t-test or non-parametric Mann-Whitney test.  
 
We calculated adjusted odds ratios (OR) and corresponding 95% confidence intervals 
(95% CI) using binary logistic regression for occurrence of outcomes and ordinal shift 
of the mRS at day 90 using the full scale for functional outcomes. Adjustment were 
made for age and baseline NIHSS.9, 10 We also assessed the effect of changed or 
continued antiplatelet regimen on outcome measures in subgroups: clinical condition 
(atrial fibrillation or not, prior stroke or not and treated with intravenous thrombolysis 
or not). We conducted subgroup analyses in these populations as their stroke risk 
recurrence 11, 12 and neurological recovery 13 are different. A p-value <0.05 was used to 
define statistical significance. All analyses were performed using IBM SPSS Version 
21.0.14 
 
Results 
A total of 1129 stroke patients met our inclusion criteria (Figure 1). Forty-eight percent 
were changed to a new antiplatelet drug post-stroke. Patient characteristics as shown in 
Table 1.  
 
There was no difference in recurrent ischaemic stroke rate between the change and 
continue groups (adjusted OR=0.97, 95% CI, 0.54-1.75; p=0.929) (Table 2). The rate of 
ICH and ECH was similar in both groups (2.4% vs. 2.6% [adjusted OR=1.02; 95% CI 
0.48-2.18, p=0.955] and 4.7% vs. 2.9% [adjusted OR=1.82; 95% CI 0.96-3.43, 
p=0.065]) respectively. Results were similar regardless of baseline factors such as atrial 
fibrillation, history of prior stroke and thrombolysed patients (Figure 2).  
 
The distribution of mRS at 90 days for change versus continue group is shown in Figure 
3. We found that change to a new antiplatelet post-stroke was associated with more 
favourable functional outcome across a full scale mRS at 90 days after adjustments for 
age and baseline NIHSS (adjusted OR, 1.48; 95% CI, 1.19-1.86; p=0.0006), compared 
with continue group. 
  
[insert Figure 1] 
 
Figure 1. Flow diagram describing the selection of data from the VISTA for the 
analysis reported. 
 
 
  
Table 1. Baseline characteristics 
 
Characteristics 
Change 
(n=538) 
Continue 
(n=591) 
p-value 
Age, years* 70.91 (11.25) 72.08 (10.49) 0.091 
Male  332 (61.7) 329 (55.7) 0.040 
Caucasian 469/527 (89.0) 531/571 (93.0) 0.020 
Current Smoker 172/524 (32.8) 145/471 (30.8) 0.491 
Baseline NIHSS† 13 (9-17) 14 (9-18) 0.036 
Medical history    
Hypertension 444/537 (82.7) 448/590 (75.9) 0.005 
Diabetes 153/538 (28.4) 155/590 (26.3) 0.414 
AF 79/537 (14.7) 135/590 (22.9) <0.001 
Heart failure 48/513 (9.4) 51/548 (9.3) 0.978 
IHD 229/525 (43.6) 204/471 (43.3) 0.922 
Prior TIA 68/490 (13.9) 67/554 (12.1) 0.391 
Prior stroke 190/527 (36.1) 133/568 (23.4) <0.001 
Thrombolysed, rt-PA 234 (43.5) 174 (29.4) <0.001 
AP duration post-stroke 
≤ 30 days 109 (20.3) 156 (26.4) 0.041 
31- 60 days 36 (6.7) 31 (5.2)  
61- 90 days 393 (73.0) 404 (68.4)  
 
All values are reported as no. (%) unless otherwise noted. *Values are reported 
as mean (SD); †median (IQR). AF=atrial fibrillation, AP=antiplatelet, IHD= 
ischaemic heart disease, NIHSS=National Institutes of Health Stroke Scale, rt-
PA=recombinant tissue plasminogen activator. TIA=transient ischaemic attack, 
SD=standard deviation, IQR=interquartile range. 
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Table 2. Clinical outcomes at 90 days (adjusted for age and baseline NIHSS). 
Outcomes 
Change 
n=538 
Continue 
n=591 
Adjusted OR 
(95% CI) 
p-value 
Recurrent 
ischaemic stroke 
22/532 
(4.1) 
25/588 
(4.3) 
0.97 (0.54-1.75) 0.929 
ICH 
13/532 
(2.4) 
15/581 
(2.6) 
1.02 (0.48-2.18) 0.955 
ECH 
25/527 
(4.7) 
17/584 
(2.9) 
1.82 (0.96-3.43) 0.065 
 
All values are reported as no. (%) unless otherwise noted. CI=confidence interval, 
ICH=intracranial haemorrhage, ECH=extracranial haemorrhage, OR=odds ratio. 
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[insert Figure 2] 
 
Figure 2. Clinical outcomes at 90 days (adjusted for age and baseline NIHSS) by 
subgroup. All values are reported as no. (%) unless otherwise noted. AF=atrial 
fibrillation, OR=odds ratio, CI=confidence interval. 
 
 
[insert Figure 3] 
Figure 3. Distribution of mRS outcome at day 90 in patients suffering ischaemic 
stroke. Diagram showing association of functional outcome at day 90 between 
change and continue group. Values provided in each box denote the percentage of 
patients belonging to a specific treatment category (change or continue) and 
representing the mRS score corresponding to the box. 
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Discussion 
In the present study we found that subjects who experience stroke while on antiplatelet 
therapy and who switch to a new class of antiplatelet regimen after stroke do not have a lower 
early recurrence rate than subjects who continue with the same antiplatelet therapy. We also 
found no difference in bleeding outcomes. Furthermore, the clinical outcomes were not 
significantly different across pre-defined subgroups. We found that change group was 
associated with an increase in the odds of a favourable functional outcome. 
 
Many patients suffer ischaemic stroke despite taking antiplatelet therapy. Some studies 
show that, in ischaemic heart disease, patients who are non-responders to aspirin and 
clopidogrel are at greater risk of subsequent ischaemic vascular event and death.15 It is 
therefore attractive to suggest that changing antiplatelet class will be of benefit, and 
reduce subsequent recurrence, in patients who are admitted with ischaemic stroke 
despite antiplatelets. This would be a cheap, immediately available way of reducing risk. 
Another study found the rate of adverse clinical outcomes was significantly higher in 
antiplatelet-regimen-modified group than those without modification.16   
 
There are no trials that show changed antiplatelet therapy after a stroke event reducing the 
risk of subsequent stroke.4 A recent retrospective cohort study by Lee et al.17 compared 
clopidogrel initiation versus aspirin re-initiation among patients with ischaemic stroke who 
took aspirin at least 30 days prior to their index of stroke. They found those who changed to 
clopidogrel after a stroke was associated with fewer vascular events than aspirin. In contrast, 
we did not find any significant relation between those who change and continue antiplatelet 
therapy. The reasons might be because our study follow-up was shorter i.e. 90 days compared 
to study by Lee et al.17 and other related trials which are normally more than 2 years.18 
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Furthermore, we divided patients into two different groups, whether they change or continue 
with the same antiplatelet therapy and not according to specific antiplatelet agent.  
 
We found those who changed antiplatelet regimen had better functional outcome at 90 
days than those in continue group. Although we tried to adjust for differences in 
baseline factors, this most likely reflects residual confounding and may reflect regional 
differences in stroke care. A physician may choose a more aggressive (or change) 
approach in patients with better prognosis. Such differences may affect functional 
outcomes but not recurrence risk. In our study the change group had lower stroke 
severity and fewer patients with atrial fibrillation at baseline, both factors are known to 
associate with an increased risk of poor outcome following an ischaemic stroke.19-23  
 
There are several limitations to this study. The analysis was performed using a non-
randomized registry data that derived from various clinical trials. Thus, selection and other 
biases could have confounded antiplatelet therapy choices. The number of included 
participants was low due to the selection criteria, the need to be on antiplatelet therapy before 
and after stroke and the need for the start dates of prior and new medications to be recorded. 
Although the recurrent ischaemic stroke rate was identical between groups, we lack statistical 
power to exclude a potentially clinically significant difference between groups. We unable to 
investigate stroke recurrence based on stroke subtype as the information are not available in 
most of the patients. We lack specific measures of medication compliance, particularly 
before the stroke, which could be a cause of failure of treatment. The effects of 
switching drugs class in such patients may be different and this will need to be 
addressed by further study. We also lack information on discharge time, which could be 
15 
 
related to compliance and to functional outcomes. We did not have information on all 
variables to calculate CHAD2VASC score and only 19% of our patients had AF. 
 
There are also strengths to our study.  The data are derived from prospective trials with 
standardized assessments and careful data monitoring, providing high quality data. In 
addition, we were able to adjust for the most important prognostic variables.  
 
In summary, we found no difference in outcomes in patients who continued the same 
antiplatelets after stroke or who changed. Despite no clear evidence for changing antiplatelet 
strategies following a cardiovascular event, over 50% of patients had their medication 
changed. This may reflect uncertainty or the fact guidelines. As recommended by the 
guideline, the selection of antiplatelet regimen after ischaemic stroke however, should be 
individualized on the basis of patient risk factor profiles, cost, tolerance and other clinical 
characteristics.4 However, this was a small retrospective analysis and future prospective trials 
will be needed.  
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VISTA-Acute Steering committee members: A.V. Alexandrov, P.W. Bath, E. Bluhmki, L. 
Claesson, J. Curram, S.M. Davis, G. Donnan, H. C. Diener, M. Fisher, B. Gregson, J. Grotta, 
W. Hacke, M.G. Hennerici, M. Hommel, M. Kaste, K.R. Lees (Chair), P. Lyden, J. Marler, 
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